189 related articles for article (PubMed ID: 7139634)
1. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity.
Sladek NE; Smith PC; Bratt PM; Low JE; Powers JF; Borch RF; Coveney JR
Cancer Treat Rep; 1982 Nov; 66(11):1889-1900. PubMed ID: 7139634
[TBL] [Abstract][Full Text] [Related]
2. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
3. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
Low JE; Borch RF; Sladek NE
Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533
[TBL] [Abstract][Full Text] [Related]
4. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
Brock N; Stekar J; Pohl J; Niemeyer U; Scheffler G
Arzneimittelforschung; 1979; 29(4):659-61. PubMed ID: 114192
[TBL] [Abstract][Full Text] [Related]
5. Rat urinary bladder epithelial lesions induced by acrolein.
Sakata T; Smith RA; Garland EM; Cohen SM
J Environ Pathol Toxicol Oncol; 1989; 9(2):159-69. PubMed ID: 2732910
[TBL] [Abstract][Full Text] [Related]
6. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
7. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Brock N; Pohl J
IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
[TBL] [Abstract][Full Text] [Related]
8. Effects of propylthiouracil on urinary metabolites of cyclophosphamide in rats.
Chijiiwa K; Linscheer WG; Raheja KL; Cho C
Cancer Res; 1983 Nov; 43(11):5205-9. PubMed ID: 6616456
[TBL] [Abstract][Full Text] [Related]
9. NTP Technical Report on the comparative toxicity studies of allyl acetate (CAS No. 591-87-7), allyl alcohol (CAS No. 107-18-6) and acrolein (CAS No. 107-02-8) administered by gavage to F344/N rats and B6C3F1 mice.
Irwin RD
Toxic Rep Ser; 2006 Jul; (48):1-73, A1-H10. PubMed ID: 17160105
[TBL] [Abstract][Full Text] [Related]
10. Single-dose cyclophosphamide for the prevention of bladder tumor implantation in F344 rats: site of drug activity.
See WA; Crist SA; Williams RD
Cancer Res; 1991 Mar; 51(5):1378-83. PubMed ID: 1997176
[TBL] [Abstract][Full Text] [Related]
11. Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide.
Gurtoo HL; Hipkens JH; Sharma SD
Cancer Res; 1981 Sep; 41(9 Pt 1):3584-91. PubMed ID: 7260917
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
13. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro.
Hales BF
Teratology; 1989 Jul; 40(1):11-20. PubMed ID: 2763206
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
15. Studies on the mechanism of urotoxic effects of N,N'-dimethylaminopropionitrile in rats and mice. 1. Biochemical and morphologic characterization of the injury and its relationship to metabolism.
Mumtaz MM; Farooqui MY; Ghanayem BI; Rajaraman S; Frankenberg L; Ahmed AE
J Toxicol Environ Health; 1991 May; 33(1):1-17. PubMed ID: 2033640
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Teicher BA; Holden SA; Goff DA; Wright JE; Tretyakov O; Ayash LJ
Cancer Chemother Pharmacol; 1996; 38(6):553-60. PubMed ID: 8823498
[TBL] [Abstract][Full Text] [Related]
18. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
20. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
Brock N; Pohl J; Stekar J
J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
